Disc Medicine files $189.9 million stock offering after APOLLO Phase 3 win in EPP
Disc Medicine registered a new at-the-market equity program with TD Cowen as it prepares an NDA resubmission for bitopertin following positive Phase 3 results.
SEC filing (2)